Mervat Mahmoud-Katheer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mervat Mahmoud-Katheer has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ali Mohamed Mousa
Family Medicine, Kuwait Oil Company, Ahmadi, Kuwait
4 shared publications - Ghaida Mubarak AlShuraiaan
Family Medicine, Kuwait Oil Company, Ahmadi, Kuwait
2 shared publications - Mayada Mahmoud Abdalla Mohamed1 shared publication
- Mechteld McNeil1 shared publication
Zouheir Ibrahim Bitar
Internal Medicine, Kuwait Oil Company, Ahmadi, Kuwait
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
A clinical constraint on lenalidomide-driven TH17 reprogramming
- 12 November 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessA clinical constraint on lenalidomide-driven TH17 reprogramming
- Open Access
- 6 October 2026
- Published by Elsevier in Biological Psychiatry Global Open Science
Could chronic estradiol deficiency contribute to suicide risk in anorexia nervosa?
- 6 October 2026
- Published by Elsevier in Biological Psychiatry Global Open Science
Open AccessCould chronic estradiol deficiency contribute to suicide risk in anorexia nervosa?
- Open Access
- 9 January 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (1) , e269032
Central hypoventilation and choking episodes revealing Chiari malformation type I
A woman in her early 40s presented with a 7-year history of recurrent choking episodes affecting solids and liquids, nocturnal choking episodes occurring 3–4 times weekly, and chronic occipital headaches spanning 14 years. Home monitoring during the COVID-19 pandemic incidentally revealed episodes of severe oxygen desaturation (70%–80%) without respiratory distress. Multiple laryngoscopies and endoscopies performed to investigate the choking episodes were normal. Review of a 14-year-old CT scan of the head performed for unrelated trauma revealed a previously overlooked crowded foramen magnum. MRI of the head and neck confirmed Chiari malformation type I (CMI) with 11 mm cerebellar tonsillar descent. Sleep study demonstrated mild sleep apnoea (apnoea–hypopnoea index 6.0) with predominantly central events (72%). This case illustrates that CMI can present with respiratory symptoms that closely mimic acquired central hypoventilation syndrome (Ondine’s curse), emphasising the importance of considering structural brain abnormalities in patients with unexplained respiratory dysfunction.
- 9 January 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (1) , e269032
Open AccessCentral hypoventilation and choking episodes revealing Chiari malformation type I
A woman in her early 40s presented with a 7-year history of recurrent choking episodes affecting solids and liquids, nocturnal choking episodes occurring 3–4 times weekly, and chronic occipital headaches spanning 14 years. Home monitoring during the COVID-19 pandemic incidentally revealed episodes of severe oxygen desaturation (70%–80%) without respiratory distress. Multiple laryngoscopies and endoscopies performed to investigate the choking episodes were normal. Review of a 14-year-old CT scan of the head performed for unrelated trauma revealed a previously overlooked crowded foramen magnum. MRI of the head and neck confirmed Chiari malformation type I (CMI) with 11 mm cerebellar tonsillar descent. Sleep study demonstrated mild sleep apnoea (apnoea–hypopnoea index 6.0) with predominantly central events (72%). This case illustrates that CMI can present with respiratory symptoms that closely mimic acquired central hypoventilation syndrome (Ondine’s curse), emphasising the importance of considering structural brain abnormalities in patients with unexplained respiratory dysfunction.
- Top Cited PapersOpen Access
- 1 January 2025
- Published by Wiley in International Journal of Endocrinology
- Vol. 2025 (1) , 6430023
Resmetirom: The First Disease‐Specific Treatment for MASH
In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction‐Associated SteatoticLiver Disease (MASLD) and MA SteatoHepatitis (MASH). This review highlights the critical epidemiological, pathophysiological, and therapeutic aspects of MASH, focusing on the novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor‐beta (THR‐β) agonist, specifically targets liver function to simulate localized hyperthyroidism, effectively reducing lipid accumulation and liver fibrosis without the systemic effects commonly associated with thyroid hormone therapy. Clinical trials, particularly the pivotal MAESTRO‐NASH trial, have demonstrated significant improvements in liver health metrics, achieving primary endpoints by resolving MASH without worsening fibrosis and showing a favorable safety profile. This paper reviews the mechanism of action, efficacy, and safety of resmetirom, providing insight into its potential to change the therapeutic landscape for patients suffering from MASH.
- 1 January 2025
- Published by Wiley in International Journal of Endocrinology
- Vol. 2025 (1) , 6430023
Top Cited PapersOpen AccessResmetirom: The First Disease‐Specific Treatment for MASH
In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction‐Associated SteatoticLiver Disease (MASLD) and MA SteatoHepatitis (MASH). This review highlights the critical epidemiological, pathophysiological, and therapeutic aspects of MASH, focusing on the novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor‐beta (THR‐β) agonist, specifically targets liver function to simulate localized hyperthyroidism, effectively reducing lipid accumulation and liver fibrosis without the systemic effects commonly associated with thyroid hormone therapy. Clinical trials, particularly the pivotal MAESTRO‐NASH trial, have demonstrated significant improvements in liver health metrics, achieving primary endpoints by resolving MASH without worsening fibrosis and showing a favorable safety profile. This paper reviews the mechanism of action, efficacy, and safety of resmetirom, providing insight into its potential to change the therapeutic landscape for patients suffering from MASH.